FGF19 analogs (such as Aldafermin), reported to be devoid of oncogenic properties, have been developed and are currently being tested in patients with metabolic dysfunction-associated steatohepatitis (MASH). Here, FGF19 is linked to metabolic dysfunction-associated steatohepatitis.